Although Eri clinical application needs optimization of treatment options and integrated safety assessment, Eri may serves as a potential treatment for NLRP3-driven diseases, including IV infection, T2D, atherosclerosis and gout. Here, NLRP3 is linked to type 2 diabetes mellitus.